Clinical Trials Browser

Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related, Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06524544 2026-06-02

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Recruiting

320 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06661720 2026-06-02

STRIKE

Phase 3 Recruiting

1,040 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04223856 2026-05-29

EV-302

Phase 3 Active not recruiting

886 enrolled 12 charts 1 FDA

Genitourinary

Urothelial Cancer

NCT05155033 2026-05-29

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Phase 2 Recruiting

78 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT03924856 2026-05-28

KEYNOTE-866

Phase 3 Completed

907 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT05562830 2026-05-27

MK-3475-04A

Phase 1/2 Recruiting

48 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06225596 2026-05-27

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Phase 2 Active not recruiting

375 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07061964 2026-05-26

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Phase 2 Recruiting

111 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03260894 2026-05-22

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Phase 3 Completed

129 enrolled 13 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT06041503 2026-05-22

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Phase 2 Recruiting

68 enrolled

Genitourinary

Adenocarcinoma of the Bladder

NCT06545955 2026-05-22

ABLE-22

Phase 3 Recruiting

250 enrolled

Genitourinary

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

NCT05614739 2026-05-19

FORAGER-1

Phase 1 Recruiting

535 enrolled

Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

NCT04626479 2026-05-18

MK-3475-03A

Phase 1/2 Active not recruiting

400 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Phase EARLY_PHASE1 Enrolling by invitation

18 enrolled

Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Phase 1/2 Completed

98 enrolled

EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT04565496 2026-05-15

PEM-PRO

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT04977453 2026-05-15

Keynote B59

Phase 1/2 Recruiting

317 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT05239728 2026-05-15

MK-6482-022

Phase 3 Active not recruiting

1,800 enrolled 1 FDA

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT07160335 2026-05-15

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

Phase 1 Recruiting

174 enrolled

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT07166601 2026-05-15

TITER

Phase 1 Recruiting

77 enrolled

GenitourinaryThoracic

Medullary cystic kidney disease 1, Carcinoma, Non-Small-Cell Lung